Close Menu

NEW YORK ─ Harvard's Wyss Institute for Biologically Inspired Engineering announced Monday that it has licensed a low-cost, affinity-based electrochemical sensing platform, called eRapid, to Sydney-based iQ Group Global for COVID-19 diagnostic testing applications.

iQ Group Global, a consortium of Australian companies, will integrate the biomarker detection technology with its transistor technology to enable specific and sensitive SARS-CoV-2 testing, Wyss Institute said.

Financial and other terms of the agreement were not disclosed.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Apr
16
Sponsored by
Thermo Fisher Scientific

With COVID-19 vaccines rolling out, clinical labs and test developers are preparing for changes in both demand for testing and types of testing for SARS-CoV-2.

May
10
Sponsored by
MeMed

Amid the COVID-19 pandemic, hospitals and intensive care units around the world have been overwhelmed by unprecedented levels of demand. 

May
13
Sponsored by
LGC SeraCare Life Sciences

As we pass the one-year anniversary of both the COVID-19 pandemic and the first Emergency Use Authorized SARS-CoV-2 PCR detection assays, there remains significant opportunity for clinical laboratories to advance testing and support improved patient management.